News and Press Releases
Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
Funding to support GMP adenovirus manufacture for a First-in-Human basket clinical trial in melanoma, lung cancer, and triple negative breast cancer
Valo Therapeutics Receives Prize at the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Awards
MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announce that Russell LaMontagne of Boston Immune Technologies and Therapeutics was chosen as the winner of the Lyfebulb-Helsinn Innovation Award, and Cesare Spadoni, PhD, of Oncoheroes Biosciences was chosen as the winner of the Squinto-LePera Award by
BioCentury Innovations Emerging Company Profile - "Valo: adding tumor antigens to oncolytic viruses"
BioCentury Innovations Emerging Company Profile "ValoTx: adding tumor antigens to oncolytic viruses" "With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immunooncology companies..." Read full article here: https://drive.google.com/file/d/1Ye_k2h4nUh9R5FxxpAlIqiH9ko5_xQtr/view?usp=sharing
Valo Therapeutics acquires PeptiENV technology from the University of Helsinki
Broadening its oncolytic virus and tumour antigen-based immuno-oncology approach across enveloped viruses
VALO THERAPEUTICS APPOINTS MICHAEL STEIN AS CHIEF EXECUTIVE OFFICER
Seasoned Healthcare Entrepreneur strengthens Management Team
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
HOUSTON and HELSINKI, Nov. 13, 2018 -- DNAtrix and Valo Therapeutics today announced an exclusive R&D collaboration to develop enhanced vaccines using DNAtrix's clinical stage viruses and Valo's proprietary antigenic peptide technology. DNAtrix's clinical stage oncolytic adenovirus platform and Valo's PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) vaccination technology will be combined to generate a novel "armed oncolytic vaccine" for cancer therapy. While oncolytic adenoviruses alone offer a promising strategy to treat cancer, in combination with PeptiCRAd, superior and durable immunological protection
Oncolytics: the dawn of a new era in cancer treatment
Published August 2, 2018 on pharmaphorum.com Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy. An oncolytic virus is defined as a genetically engineered or naturally occurring virus that can selectively replicate and kill cancer cells without harming healthy tissues. In contrast to gene therapy, where a virus is used as a mere carrier for transgene delivery, oncolytic virus
Nature: Cancer-killing viruses show promise — and draw billion-dollar investment
Encouraging trial results spur interest from researchers and drug giants.
Valo Therapeutics is developing a virus-based immunotherapy to defeat cancer
There have been major developments in cancer treatment in recent years. However, treatment of advanced, metastasized tumours remains challenging, and still requires search for new solutions. Valo Therapeutics is currently developing an oncolytic virus-based immunotherapy that is scheduled to enter clinical trials in upcoming years.
Valo Therapeutics Recruits Charlotta Backman as VP Clinical Operations and Regulatory Affairs
Charlotta Backman (M. Sc) has a strong background in clinical research, with over 15 years of experience in start-up, conduct and close-out of Phase I to Phase IV clinical trials, including trials in oncology and vaccines, but also in hypertension and dermatology. Charlotta joined Valo Therapeutics in March 2017, to oversee and lead all clinical operations and regulatory affairs. Over the years, Charlotta has also gained experience from interactions with several regulatory authorities in the EU and in the US
Valo Therapeutics receives $4.6 million non-dilutive funding from Tekes, in order to accelerate development of a novel oncolytic virus-based cancer immunotherapy
Helsinki, Finland, July 4, 2017. The Finnish Funding Agency for Innovation, Tekes, has granted Valo Therapeutics a $4.6 million non-dilutive loan for the preparation of a Phase I trial of a novel oncolytic virus-based cancer immunotherapy called PeptiCRAd. Valo Therapeutics has now raised $8 million (including $3.4m seed capital in January 2017) towards its mission to provide cancer patients with less toxic and longer lasting therapeutic options. Valo Therapeutics aims at combining the PeptiCRAd technology with check point inhibitors in
Adenoviruses and the immune system join forces against cancer
IDIBELL researchers have developed an oncolytic virus capable of redirecting the patient's immune system against their tumor cells
Immuno-oncology News: Valo Therapeutics Developing Unique Viral-particle Cancer Vaccine
A new cancer vaccine that uses viral particles to trigger strong immune responses against cancer cells is being developed by Valo Therapeutics.
Drug Discovery and Development- "Immunotherapy: Training The Body to Fight Cancer"
Top researchers in the field of immuno-oncology show promising results using peptide / antibody vaccine combination treatments in terminally ill patients with metastatic tumours
Valo Therapeutics closes seed fundraising round to develop a novel oncolytic virus-based cancer immunotherapy
A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.
Valo Therapeutics päätti siemenrahoituskierroksen kehittääkseen uutta onkolyyttiseen virukseen perustuvaa syövän immunoterapiaa
Valo Therapeutics, spin-out -yhtiö Helsingin yliopistosta, kehittää uutta onkolyyttiseen virukseen perustuvaa syövän immunoterapiaa, jolla voidaan hoitaa useita eri syöpätyyppejä.
Oncolytic Viruses "undervalued" technology with strong growth perspectives
Major acquisitions (>$1bn) have been a game changer for the field of oncolytic viruses, now recognized as a promising new therapeutic approach for cancer treatment.
Valo Therapeutics recruits Petri Priha as Vice President CMC
Petri Priha has recently joined Valo Therapeutics to fulfill the position of Vice President of CMC, bringing over 20 years of Biopharmaceutical industry and product development experience to the company.